Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Long-Term Projected Growth Rate for the Nucleic Acid Based Gene Therapy Market, and What Are the Key Drivers?

The market size for nucleic acid-based gene therapy, which has been experiencing significant growth in recent years, is projected to increase from $0.81 billion in 2024 to $0.88 billion in 2025. This growth, representing a compound annual growth rate (CAGR) of 9.4%, is attributed to several factors. These include a growing understanding of human genetics, an increased demand for personalized medicine, an expanding pipeline of gene therapy products, increased government backing for gene therapy, and the underlying genetic disorders and cancer therapies.

Projected for a swift expansion in the coming years, the nucleic acid based gene therapy sector is set to escalate to a valuation of $1.33 billion by 2029, progressing at a compound annual growth rate of 10.7%. The upward trajectory in the forecast period is forecasted to be driven by factors such as a broadening of indications, surges in funding, heightened patient advocacy and awareness, an upswing in gene therapy research and development investments, an widening application scope of gene therapy, and treatment of rare diseases. Key trends during the forecast period encompass ex vivo gene editing, progressions in in vivo gene editing, combined therapies, targeted delivery systems, gene editing for rare diseases, and the use of non-viral vectors.

What Industry-Specific Factors Are Fueling the Growth of the Nucleic Acid Based Gene Therapy Market?

The increased financial backing from both the government and corporations is anticipated to stimulate the need for nucleic acid-based gene therapy. Nucleic acid treatments are counterparts of acids or proteins that naturally occur and are crucial for genetic expression. Conventional treatments offer no cure for diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. The foundation of these drug classes is formed by genetic profiling and identification of molecular targets. Compared to traditional treatments, nucleic acid medication holds a higher potential to treat these diseases effectively as it targets the disease’s genetic roots, providing a permanent solution. The upward trajectory in financial backing from the government and companies engaged in the gene therapy market is poised to boost the nucleic acid-based gene therapy market. For instance, the National Institute of Health (NIH) pledged an annual investment of $34 million over the next five years, starting from August 2022, for HIV treatment research. This state support towards gene therapies is expected to propel the growth of the nucleic acid-based gene therapy market.

Request Your Free Nucleic Acid Based Gene Therapy Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=2820&type=smp

Which Companies Are Leading the Charge in Expanding the Nucleic Acid Based Gene Therapy Market?

Major companies operating in the nucleic acid based gene therapy market include Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.

What Trends Are Poised to Drive the Future Success of the Nucleic Acid Based Gene Therapy Market?

In March 2023, US biotechnology firm Moderna, Inc. forged a partnership with Generation Bio. The objective of the collaboration is to create new nucleic acid therapies, with the ability to reach immune cells, expedite both companies’ pipelines of non-viral genetic medicines, and also finance all the associated research and development activities, which include a pre-payment for research initiatives. Generation Bio, a US biotechnology organization, specializes in nucleic acid-based gene therapy.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

What Are the Key Components of the Nucleic Acid Based Gene Therapy Market, and How Do Its Segments Perform?

The nucleic acid based gene therapy market covered in this report is segmented –

1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies

2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases

3) By End User: Hospitals And Clinics, Academic And Research Institutes

Subsegments:

1) By Anti-Sense And Anti-Gene: Oligonucleotide Therapeutics, Peptide Nucleic Acids (PNA), Morpholino Oligomers (MO)

2) By Short Inhibitory Sequences (siRNA): Synthetic siRNA, Encapsulation/Delivery Systems for siRNA, Target-specific siRNA Therapies

3) By Gene Transfer Therapy: Viral Vectors (Adenovirus, Lentivirus, Retrovirus, AAV), Non-Viral Vectors (Liposomes, Electroporation, Gene Gun)

4) By Nucleoside Analogs: Purine Analogs, Pyrimidine Analogs

5) By Ribozymes: Trans-Splicing Ribozymes, Hammerhead Ribozymes

6) By Aptamers: RNA Aptamers, DNA Aptamers, Small Molecule Binding Aptamers

7) By Other Technologies: CRISPR-based Gene Editing, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs)

What Are the Top Regions Fueling Growth in the Nucleic Acid Based Gene Therapy Market?

North America was the largest region in the nucleic acid-based gene therapy market in 2023. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

What Defines the Scope of the Nucleic Acid Based Gene Therapy Market?

Nucleic acid-based gene therapy is a medical treatment approach that uses nucleic acids (such as DNA or RNA) to modify or manipulate genes within a patient’s cells to treat or prevent diseases. This therapy aims to address the root cause of a disease at the genetic level by directly intervening in the genetic material that leads to the malfunctioning of cells.

Browse Through More Similar Reports By The Business Research Company:

Gene Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

NGS-Based RNA-Sequencing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Medical Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: